Drugs / ARC-AAT
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02363946 | Feb 2015 → Nov 2016 | alpha 1-antitrypsin deficiency | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARC-AAT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02363946 ↗ |
| Action | Inhibit | “This study evaluated an RNAi therapeutic to silence production of AAT.” PMID 29572094 ↗ Mar 2018 |
| Modality | Small interfering RNA (siRNA) | “RNA interference-based, liver-targeted therapeutic” NCT02363946 ↗ |
| Route | Intravenous | “Healthy volunteers and AATD patients will be randomized to receive a single intravenous injection of either ARC-AAT or Placebo in double-blind fashion.” NCT02363946 ↗ |